Acellular dermal matrix (ADM) injection, unlike conventional synthetic fillers (e.g., hyaluronic acid, CaHA, PLLA, PDLLA, etc.), is a regenerative injectable graft developed by decellularizing and micronizing human-derived dermal tissue. ADM filler is differentiated from existing fillers in that it preserves the extracellular matrix (ECM), including collagen, elastin, glycosaminoglycans (GAGs), and various growth factors, and thus has a fundamental healing mechanism that goes beyond simple volume augmentation and induces tissue regeneration, angiogenesis, and cellular infiltration.
I am excited and thrilled to introduce this new treatment.

In particular, areas of thin skin such as neck wrinkles, dark circles, sunken scars, and fine wrinkles are known to be at high risk for Tyndall effect, abnormal swelling, and vascular complications when hyaluronic acid filler is administered.
In contrast, Human Injectable ADM (Hi-ADM) filler provides a structural scaffold for the dermis-subcutaneous tissue, thereby demonstrating stable and natural effects even on thin skin, and can be expected to have additional effects such as skin texture improvement through ECM remodeling, enhanced moisture retention, and promotion of long-term collagen synthesis.

Additionally, high-resolution ultrasound and Doppler-based pre-planning techniques further enhance safety and precision in all procedures, not just ADM fillers.
In particular, in high-risk anatomical areas such as the infraorbital hollow, tear trough, and neck folds, low-pressure, retrograde injection using a cannula after confirming the location and thickness of blood vessels, lymphatic vessels, and retaining ligaments has become a key strategy to increase safety and predictability.